Nucleix has received the funding for Lung EpiCheck, a screening diagnostic blood test for early detection of lung cancer. Israeli cancer detection and screening company Nucleix announced today that it has received €2.5 million in funding, following its application to the highly-selective EIC pilot SME Instrument Phase II European program. EIC pilot SME Instrument Phase 2 is part of Horizon 2020, a €80 billion funding program managed by the European Commission and dedicated to innovation and research.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click on the link inside the
email and you’re good to go.